Fig. 6: The combination of miR-34c-3p and RO3306 affects proliferation and apoptosis.
From: miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer
a Proliferation analysis of KRAS-mutant A549 cells transfected with miR-34c-3p and b primary epithelial cells from PT#18 co-transfected with miR-34c-3p and a KRAS mutant vector (left panel) or with control vector (pCMV) (right panel), in combination or not with RO3306. Proliferation was analysed after 24 and 96 h of treatment. Experiments were performed in technical triplicates and repeated twice. Data are presented as mean ± SD. Two-way ANOVA was used for comparisons (A549 miR-34c-3p vs miR-34c-3p + R0 = 3306; and PT#18 and KRASmut/miR-NC + RO-3306 vs KRASmut/miR-34c-3p + RO3306). Bar graph represents the percentage of viable cells upon 96 h of transfection, comparing NSCLC cells expressing RAS wild type (pCMV) or KRAS mutated (pKRASmut) c Annexin-V and propidium iodide staining of A549 cells transfected with miR-34c-3p and treated with RO3306. Cells transfected with scrambled miRNA were used as control. The graph on the right reports the quantification of the number of live cells and apoptotic cells in each experimental point. Data are presented as mean ± SD. ANOVA was used for statistical analysis. (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). Experiments were performed two times.
